Track topics on Twitter Track topics that are important to you
Secukinumab Showed Sustained Improvements After Years PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Secukinumab Showed Sustained Improvements After Years articles that have been published worldwide.
We have published hundreds of Secukinumab Showed Sustained Improvements After Years news stories on BioPortfolio along with dozens of Secukinumab Showed Sustained Improvements After Years Clinical Trials and PubMed Articles about Secukinumab Showed Sustained Improvements After Years for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Secukinumab Showed Sustained Improvements After Years Companies in our database. You can also find out about relevant Secukinumab Showed Sustained Improvements After Years Drugs and Medications on this site too.
Secukinumab treatment has previously been shown to significantly improve the signs and symptoms of active ankylosing spondylitis (AS), with responses sustained through 2 years. Here, we report the long-term (3 years) efficacy and safety of secukinumab in the MEASURE 2 study.
Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has been shown to have significant efficacy and a favorable safety profile in the treatment of moderate to severe psoriasis and psoriatic arthritis.
Secukinumab is a fully human monoclonal antibody that can selectively neutralize interleukin-17A, and its excellent efficacy has been demonstrated in clinical trials for psoriasis. The aim of our study is to assess long-term efficacy and safety of secukinumab for 52 weeks in real-world clinical practise in our facility. A total of 83 patients (71 with psoriasis vulgaris and 12 with psoriatic arthritis) were included, and 49 of them were bio-switched patients. Psoriasis Area and Severity Index (PASI) 75 and ...
Secukinumab is an anti-IL 17A monoclonal antibody currently licensed for the treatment of plaque psoriasis, psoriatic arthritis and ankylosing spondylitis. However, although inflammatory bowel disease is a disorder with related immune characteristics, secukinumab has not proved to be effective in these diseases. In fact, negative results in a clinical trial designed to assess its efficacy in patients with Crohn disease have been published. On the other hand, the drug fact sheet states that secukinumab shoul...
Refractory pityriasis rubra pilaris (PRP) often is treated off-label with the same biologic therapies that are approved for the treatment of psoriasis, most commonly tumor necrosis factor (TNF) α antagonists and ustekinumab; however, the IL-17A antagonist secukinumab also has shown efficacy in the treatment of PRP. We report 2 new cases of severe refractory PRP that responded rapidly to treatment with secukinumab.
The ACCESS-model offers integrated care including assertive community treatment to patients with psychotic disorders. ACCESS proved more effective compared to standard care (ACCESS-I study) and was successfully implemented into clinical routine (ACCESS-II study). In this article, we report the 4-year outcomes of the ACCESS-II study. Between May 2007 and December 2013, 115 patients received continuous ACCESS-care. We hypothesized that the low 2-year disengagement and hospitalization rates and significant imp...
To evaluate minimal disease activity (MDA) among psoriatic arthritis (PsA) patients receiving secukinumab through 2 years in the FUTURE 2 study (NCT01752634).
We present the case of an HIV-negative patient clinically diagnosed with relapsing-remitting MS who achieved significant disease improvement on Combivir (zidovudine/lamivudine). Within months of treatment, the patient reported complete resolution of previously unremitting fatigue and paresthesiae, with simultaneous improvements in lesion burden detected by MRI. All improvements have been sustained for more than three years. This response may be related to the action of zidovudine as a known inhibitor of EBV...
Head-to-head randomised studies comparing ixekizumab and secukinumab in the treatment of psoriasis are not available.
Understanding genetic variations is important in predicting the treatment response and forms the basis for identifying new pharmacogenetic and pharmacogenomic targets for the treatment of psoriasis. Limited data are available for the efficacy of secukinumab in relation to genetic markers.
The aim of this study was to investigate if endurance training during juvenile life 'reprograms' the heart and leads to sustained improvements in the structure, function, and morphology of the adult heart. Male Wistar Kyoto rats were exercise trained 5 days/week for four weeks in either juvenile (5-9 weeks of age), adolescent (11-15 weeks of age) or adult life (20-24 weeks of age). Juvenile exercise training, when compared to 24 week old sedentary rats, led to sustained increases in left ventricle (LV)...
Psoriatic arthritis is an inflammatory arthritis without a clear etiology. Biological therapy has become key for its treatment, especially in more severe cases. There are several alternatives for biological treatment, including secukinumab. However, it is not clear how effective and safe it is, which is particularly relevant considering its high cost.
Limited studies have explored the impacts of exposure to sustained high levels of air pollution (air pollution wave) on mortality. Given that the frequency, intensity and duration of air pollution wave has been increasing in highly polluted regions recently, understanding the impacts of air pollution wave is crucial. In this study, air pollution wave was defined as 2 or more consecutive days with air pollution index (API) > 100. The impacts of air pollution wave on years of life lost (YLL) due to non-ac...
Secukinumab and adalimumab are approved for adults with active psoriatic arthritis (PsA). In the absence of direct randomized controlled trial (RCT) data, matching-adjusted indirect comparison can estimate the comparative effectiveness in anti-tumor necrosis factor (TNF)-naïve populations.
A recent review by Hu et al. highlights the use of biologic switching in clinical practice to maximize skin clearance and improve clinical outcomes. However, efficacy and safety outcomes of ixekizumab therapy in patients who did not respond to, lost response, or were intolerant to secukinumab was not mentioned in their review and is lacking. As such, dermatologists may be hesitant to switch between interleukin (IL)-17A antagonists, electing to try an alternative biologic with a different mechanism of actio...
The purpose of this study was to determine whether balance and mobility training (BMT) or balance and mobility plus cognitive training (BMT + C) would improve obstacle clearance and reaction time (RT); whether further improvements would be exposed in the BMT + C group relative to the BMT group; and whether possible improvements would be sustained at the follow-up. Healthy older adults were allocated to the BMT (n = 15; age: 70.2 ± 3.2), BMT + C (n = 14; age: 68.7 ± 5.5), or con...
We sought to determine whether sustained poverty is associated with change in body mass index (BMI) among 4,762 black and white adults of the Coronary Artery Risk Development In Young Adults study. Household income in the past year and current BMI were measured at seven visits between 1990 and 2015. Sustained poverty was the proportion of visits during which household income was below 200% of the federal poverty level (range, 0%-100%). Sustained poverty and BMI were time-updated. Mean age in 1990 was 30 yea...
Biochar has been recognized as an efficient soil amendment for cadmium remediation in recent years. In the present study, biochar was prepared using walnut shell, and it was incubated in Cd(NO) and kaolin for 15 days. Different chemical forms of cadmium in kaolin and biochar were determined, and the stability of biochar was evaluated by R using TGA analysis. It was found that walnut shell derived biochar could reduce the mobility of cadmium. After incubation, the R value increased from 61.31% to 69.57%-72...
Over the past years, there is a growing number of newly diagnosed pediatric patients with Crohn's disease (CD). Severe course of CD often requires biological treatment with Infliximab (IFX). Loss of response to biological treatment is a major problem. Mean platelet volume (MPV) was reported as a good marker of sustained response to IFX therapy in adults. This study is to determine whether MPV measured prior to IFX therapy and a er its third dose can be used as a predictive marker of sustained response to bi...
The effects of surface bioactivity and sustained-release of genistein from a mesoporous magnesium-calcium-silicate/PK composite stimulating cell responses in vitro, and promoting osteogenesis and enhancing osseointegration in vivo.
The surface of a mesoporous magnesium-calcium-silicate (m-MCS)/polyetheretherketone (PK) composite (MPC) was modified by sand blasting, and genistein (GS) was loaded inside the nanopores of the m-MCS on the modified MPC (MPCm) surface. The results showed that compared with MPC, the surface roughness and hydrophilcity of MPCm obviously improved with more m-MCS exposed on its surface. Moreover, no obvious differences in surface roughness and hydrophilcity were found between MPCm and GS loaded MPCm (MPCm-Ge), ...
To evaluate the outcome of current treatment for creatine transporter (CRTR) deficiency, we developed a clinical severity score and initiated an international treatment registry. An online questionnaire was completed by physicians following patients with CRTR deficiency on a treatment, including creatine and/or arginine, and/or glycine. Clinical severity score included 1) global developmental delay/intellectual disability; 2) seizures; 3) behavioural disorder. Phenotype scored 1-3 = mild; 4-6 = mode...
Despite major technical improvements in the care of children requiring renal replacement therapy (RRT) before 2 years of age, the management of those patients remains challenging and transplantation is generally delayed until the child weighs 10 kg or is 2 years old. In this national cohort study, we studied patient and graft survival in children starting RRT before 2 years of age to help clinicians and parents when deciding on RRT initiation and transplantation management.